| Recovery of ovarian function and pregnancy in a patient with AML after myeloablative busulphan-based conditioning regimen. | |
| | |
MedLine Citation:
|
PMID: 21423042 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We report a rare case of ovarian function recovery and pregnancy after hormone-replacement therapy (HRT) in the acute myeloblastic leukemia (AML) patient in third complete remission received hematopoietic stem cell transplantation (HSCT) with busulphan-based conditioning regimen. Successful engraftment of the donor cells and full donor's chimerism was achieved without the signs of leukemia. One year after HSCT the patient received a course of HRT as a treatment of hypergonadotropic hypogonadism. After 12 months of HRT the recovery of ovarian function was confirmed. Eight years after the HSCT spontaneous pregnancy occurred; heartbeat of the fetus was registered on week 7. Three weeks later a nonsevere vaginal bleeding occurred and the ultrasound examination showed a nondeveloping pregnancy. Genetic examination of the abortion material showed a full triploid genotype (69 XXX). To our knowledge this is a first case of ovarian function restoration and spontaneous pregnancy in a AML patient after multiple courses of high-dose chemotherapy and busulphan-based myeloablative conditioning for HSCT. |
| | |
Authors:
|
Dmitry N Balashov; Ludmila I Papusha; Tatiana A Nazarenko; Pavel E Trakhtman; Nino A Revishvili; Alexei A Maschan; Marina I Persiantseva; Anna V Andriutsa; Elena V Skorobogatova; Yulia V Skvortsova; Alexander G Rumiantsev |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Journal of pediatric hematology/oncology Volume: 33 ISSN: 1536-3678 ISO Abbreviation: J. Pediatr. Hematol. Oncol. Publication Date: 2011 May |
Date Detail:
|
Created Date: 2011-04-25 Completed Date: 2011-06-30 Revised Date: 2011-10-06 |
Medline Journal Info:
|
Nlm Unique ID: 9505928 Medline TA: J Pediatr Hematol Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: e154-5 Citation Subset: IM |
Affiliation:
|
Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia. bala8@yandex.ru |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Antineoplastic Agents / administration & dosage, adverse effects Busulfan / administration & dosage*, adverse effects Child Combined Modality Therapy Female Hematopoietic Stem Cell Transplantation* Humans Hypogonadism / drug therapy Leukemia, Myeloid, Acute / drug therapy* Myeloablative Agonists / administration & dosage, adverse effects Ovary / physiology* Pregnancy Pregnancy Outcome Recovery of Function* Transplantation Conditioning / adverse effects, methods* Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Myeloablative Agonists; 55-98-1/Busulfan |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Ocular Hypotensive Effect of Tafluprost in Latanoprost Low-responder Cynomolgus Monkeys.
Next Document: Higher urinary excretion of inorganic phosphate during early induction chemotherapy predicts a good ...